Research Impact

h-index

N/A

Research impact score

Publications

0

Total publications

Trial Results

0

Published trial results

Citations

0

Total citations

Drug Portfolio

Analytics

Trial Phases

Phase 21

Trial Status

Recruiting1

Role Distribution

Principal Investigator1
PI Rate100%

Activity Timeline

Clinical Trials (1)

NCT06044311Phase 2Recruiting
Oral TGF-beta Receptor I Inhibitor Vactosertib in SOC Chemoradiotherapy for Esophageal Adenocarcinoma
Adenocarcinoma EsophagusLocally Advanced AdenocarcinomaSiewert Type I Adenocarcinoma of Esophagogastric Junction+1 more
PrincipalinvestigatorStart date: 2024-09-30

Research Network

Collaboration Network

1 collaborators·0 connections
Network Legend
KOL
Current Investigator
CO
High-influence Collaborator
CO
Collaborator
Click: view details
Double-click: go to profile
Drag: move node

Research Areas & Affiliations

Similar Key Opinion Leaders

Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.

10 similar investigators found

Andrey Ryabov, MD, PhD

P.Herzen Moscow Oncological Research Institute

Related
5 trials

Shared therapeutic areas:

Siewert Type I Adenocarcinoma of Esophagogastric JunctionSiewert Type II Adenocarcinoma of Esophagogastric Junction
Similarity Score15%

Pavel Smirnov

P.Herzen Moscow Oncological Research Institute

Related
3 trials

Shared therapeutic areas:

Siewert Type I Adenocarcinoma of Esophagogastric JunctionSiewert Type II Adenocarcinoma of Esophagogastric Junction
Similarity Score15%

Vladimir Khomyakov, MD, PhD

P.Herzen Moscow Oncological Research Institute

Related
4 trials

Shared therapeutic areas:

Siewert Type I Adenocarcinoma of Esophagogastric JunctionSiewert Type II Adenocarcinoma of Esophagogastric Junction
Similarity Score15%

peichun sun, MD,PH.D

Henan Provincial People's Hospital

Related
1 trials

Shared therapeutic areas:

Siewert Type II Adenocarcinoma of Esophagogastric Junction
Similarity Score8%

Jeffrey Olsen, MD

University of Colorado, Denver

Related
1 trials

Shared therapeutic areas:

Adenocarcinoma Esophagus
Similarity Score8%

Sandro Mattioli - Alma M Studiorum-University, MD

Department of Medical and Surgical Sciences

Related
1 trials

Shared therapeutic areas:

Siewert Type II Adenocarcinoma of Esophagogastric Junction
Similarity Score8%

Joyson Poulose, MD

Guthrie Medical Group, PC/Robert Packer Hospital

Related
1 trials

Shared therapeutic areas:

Adenocarcinoma Esophagus
Similarity Score8%

lei wang, MD,PH.D

General Hospital of Ningxia Medical University

Related
1 trials

Shared therapeutic areas:

Siewert Type II Adenocarcinoma of Esophagogastric Junction
Similarity Score8%

Dr Avani Athauda

Royal Marsden NHS Foundation Trust

Related
1 trials

Shared therapeutic areas:

Adenocarcinoma Esophagus
Similarity Score8%

xuejun sun, MD,PH.D

First Affiliated Hospital Xi'an Jiaotong University

Related
1 trials

Shared therapeutic areas:

Siewert Type II Adenocarcinoma of Esophagogastric Junction
Similarity Score8%

Publications (0)

No publications found for this investigator.

Clinical Trials (1)

Showing 1 of 1 trials

NCT06044311Phase 2PrincipalInvestigator

Oral TGF-beta Receptor I Inhibitor Vactosertib in SOC Chemoradiotherapy for Esophageal Adenocarcinoma

Adenocarcinoma EsophagusLocally Advanced AdenocarcinomaSiewert Type I Adenocarcinoma of Esophagogastric Junction+1 more
Recruiting

All 1 trials loaded